Table of contents
At a glance
Which requirements have applied to veterinary GMP computerised systems since July 2026?
Implementing Regulation (EU) 2025/2091, including Annex IV on computerised systems, applies to veterinary medicinal product manufacturing within its scope. Implementing Regulation (EU) 2025/2154, including Article 20, addresses active substances used as starting materials within its scope. Both apply from 16 July 2026. Identify the relevant manufacturing and data process, then compare existing controls with the applicable current text.
- Veterinary and active ingredient manufacturing require segregated source tracing.
- The correspondence table assists in locating information; it does not replace the current regulatory text.
- Existing evidence remains assessable and usable; its appropriateness must be evaluated on a case-by-case basis.
1. Use the current regulatory stance instead of a generic Annex-11 reference
Source date is 7 October 2026. The European Commission implements veterinary GMP separately from the human medicinal product sector. Regulations 2025/2091 and 2025/2154 are applicable from 16 July 2026. For Regulation 2025/2091, the consolidated position as of this date is considered, including the amendment introduced by Regulation 2026/857.
The commonly recognized control topics do not disappear as a result. However, for a current and demonstrable traceability, it should be clearly evident which specific regulation governs the particular activity. "We work according to Annex 11" as a standalone source attribution for the veterinary process is insufficiently precise.
This article provides an IT-based classification. It does not replace a comprehensive assignment of all product- and activity-specific special regulations, such as those for specific biological manufacturing processes or sterile processing.
2. Assign the activity prior to the system name
An ERP, LIMS, or document management system can support a range of different functions. What matters most is not merely which company holds the license, but which manufacturing or quality process utilizes the specific function. Therefore, capture product type, activity, data used, and subsequent decisions.
Regulation 2025/2091 covers veterinary medicines; its Annex IV classifies computerised systems based on their relevance to manufacturing and the pharmaceutical quality management system. Regulation 2025/2154 addresses active substances used as starting materials and includes specific exemptions and references. These boundaries must be assessed in accordance with Article 1, and shall not be inferred solely from the term "active substance".
For commercial purposes only, without connection to the quality system, it is necessary to distinguish from quality-related dependencies. If a purportedly commercial master date, for example governing material identity or usage, exerts control, its actual impact must be evaluated.
3. Use the correspondence table to locate the relevant provisions
The European Commission provides a correspondence table. Among other entries, it maps the former Annex 11 to Annex IV of 2025/2091. Use it to locate earlier topics. Check the actual text before treating any two requirements as identical.
Therefore, after identifying the specific passage, compare it with the following internal work aid, which references only a few IT aspects and deliberately draws from different sources. This document is not a complete regulatory gap analysis.
| Area under consideration | Current Entry | Practical Comparison |
|---|---|---|
| Recorded veterinary medicinal product manufacturing | 2025/2091 Art. 1, Annex IV | Assign system purpose, risk-based validations, and operational management |
| Active pharmaceutical ingredient manufacturing within scope | 2025/2154 Art. 1 and 20 | Review the IT requirements of this area. |
| Current Annex-11 Assignment | EU Compliance Table, Page 8 | Locate the relevant section in Appendix IV and compare with the original text |
| Data modifications | 2091 Annex IV, Section IV.7 or 2154 Article 20, paragraph 4 | Note different phrasing and specific data scope |
| Human- and veterinary co-use | Separate evaluation of intended use per process | Conduct joint control with multiple traceable source references |
4. Assess the adequacy of existing evidence
An existing test is not rendered obsolete merely because its source reference changes. Assess its current purpose, status, and actual control function. A documented additional accuracy verification for critical manual inputs may remain relevant; the specific scope must align with current usage.
Conversely, an updated heading does not constitute evidence that an open control question has been resolved. Separate the three findings: existing appropriate evidence, required editorial source correction, and actual substantive gap. This distinction prevents both unnecessary repetition and mere re-labeling.
Compare the requirements for data modifications within the respective scope of application. Annex IV, Section IV.7 of Regulation (EU) 2025/2091 links the implementation of a system-generated audit trail to a risk assessment. When relevant data is modified or deleted, the rationale must be documented; audit trails must be accessible, convertible into general understandable form, and regularly reviewed. Article 20, paragraph 4, of Regulation (EU) 2025/2154 explicitly requires, for the listed active substance systems covered therein, the recording and review of all data modifications within the audit trail. Do not transfer one formulation without proper evaluation to the other area.
5. Example: Comparison for a shared laboratory facility
A laboratory uses a LIMS for a veterinary finished product process and a separately tracked active ingredient process. For this example, four control questions are selected: sample assignment, critical manual entry, data modification, and restoration. This represents a limited scope of operational considerations, not a complete list of regulatory requirements.
The initial review identifies two relevant existing validations: a simple source correction and one open technical question. All four control questions have thus been addressed. However, no compliance rate can be derived from this: the open question may be highly relevant to the intended use.
The matrix clearly shows which action follows from each finding. It is assumed herein that existing documentation is actually appropriate; actual records were not reviewed.
| Control question | Accepted finding | Justified next step |
|---|---|---|
| Sample assignment in the veterinary process | Existing test covers current status and data pathway. | Document fit and supplement current source assignment |
| Critical manual entry | Appropriate control is demonstrated for both considered processes. | Maintain traceability to specific intended use. |
| Restoration procedure | Appropriate evidence available; outdated source reference on the cover page | Reference controlled correction, test not to be repeated solely for that reason |
| Change history in active ingredient process | Coverage and review of specific data modifications unclear | Art. 20 paragraph 4 specifically to be verified; define data scope, control and provide evidence |
6. Consider common technology and separate responsibility
Common infrastructure can enable shared validation evidence. It does not harmonize differing process responsibilities and application scopes. Document the functions and data used by both areas, as well as where configurations, roles, or subject-matter authorizations differ.
Include suppliers and outsourced activities within the actual scope of operations. A contract or supplier package must cover the relevant responsibilities and services. Its suitability for a specific use is not established solely by its existence.
Changes to these relationships should also be evaluated. A common interface modification may affect both processes, while a process-specific specification change may impact only part of the process. The assignment should assist in identifying the appropriate scope of evidence.
7. Preparation for QA, Regulatory and IT
Regulatory or the responsible quality function determines product and activity alignment. Process owners describe actual usage; IT provides system status, data flows, and existing evidence. A small and medium-sized enterprise (SME) may commence with a representative process and subsequently apply the method to other applications.
- Determine the product, manufacturing step, and specific usage limitations.
- Document the current version and application date.
- Assign system functions to specific activities.
- Locate earlier source references using the correspondence table.
- Compare the original passage and existing control directly.
- Differentiating editorial correction from an actual detection gap.
- Evaluate open technical questions prior to completion and take responsibility for follow-up.
8. Avoid blanket transitions in both directions
"Everything remains unchanged" may overlook new or rephrased references. "Everything must be revalidated" disregards the potential value of existing appropriate evidence. A credible transition instead identifies the current reference for each relevant question and specifies the required action.
You should not automatically incorporate all human medicinal product guidelines, FDA requirements, or draft documents into the veterinary process. Additional markets or activities may justify further requirements; however, these must be specifically identified.
The result should be a clear, traceable assignment with clearly defined gaps. A long list of new paragraph numbers without reference to actual system usage provides neither support for operational decision-making nor clarity for subsequent explanation of controls.
Project experience and collaboration
Map existing controls to the applicable veterinary requirements
With Quality and the process owners, we identify which uses concern veterinary medicinal products and which concern their active substances. We compare existing system evidence with the legal basis applicable to each since July 2026. Correcting a reference may call for a different response from closing a gap in how data changes are recorded and reviewed. We plan additions around actual use. This assessment neither requires blanket revalidation nor automatically approves all existing systems.
Frequently asked questions about Veterinary medicines GMP in 2026
When do the two Veterinary GMP Regulations come into effect?
Is Annex 11 the sole reference for veterinary processes?
Which regulation addresses computersystems in active ingredient manufacturing?
For the active substances covered by 2025/2154, Article 20 is the actual entry. Check previously Article 1 with its limits, exceptions and additional references. Not every activity with a material called an active substance is to be treated the same without further classification.
Sources: [2]
Must all existing tests be reperformed?
Not solely due to the new legal basis. Assess whether an existing validation record already covers the current requirements, configuration, and usage. A simple source correction does not address a genuine technical gap. Derive targeted supplements or repetitions accordingly; neither blanket retesting nor a general release is justified thereby.
Can human and veterinary processes use the same LIMS?
Shared usage is possible provided the distinct application areas are clearly understood. Common technology requires well-defined roles, data pathways, and clear assignment of applicable requirements. Assess which controls cover both processes and where differences necessitate additional validation evidence.
Why are two different locations referenced in the audit trail?
Are commercial functions always outside the scope of the IT qualification?
No, a blanket exclusion based on module names would be too crude. What matters most is the linkage to the recorded quality or manufacturing process. A master date, despite its commercial origin, can still serve as a relevant material assignment or usage control.
Sources: [1]
What is the most practical first auxiliary tool for a small manufacturer?
A mapping of activity, system function, current source, and existing evidence. Start with a specific data pathway and flag open questions. This enables clear identification of whether a document correction is sufficient or whether a control or its evidence requires further technical substantiation.
Sources and review date
Source date: 7 October 2026. EU Veterinary GMP; consolidated version of Regulation 2025/2091 dated 16 July 2026 and Regulation 2025/2154. Specific application limits and product-specific derogations shall be determined on a case-by-case basis. Tables and laboratory scenarios are standalone reference tools and do not constitute a complete legal or operational audit.
- European Union: Implementing Regulation (EU) 2025/2091Regulation (EU) of 17 October 2025, consolidated version as of 16 July 2026 including Regulation (EU) 2026/857; Articles 1 and 46, Annex IV I–IV.17. Official original text and consolidated version as of 7 October 2026, directly read.
- European Union: Implementing Regulation (EU) 2025/2154Regulation of 17.10.2025, OJ 27.10.2025; Articles 1, 20, 21 and 77 read directly on 07.10.2026. Active substances as starting materials for veterinary medicinal products; applicable since 16.07.2026.
- European Commission: EudraLex Volume 4 – current document inventoryReviewed on 07.10.2026: Annex 11 Revision January 2011; dedicated veterinary area applying Regulations 2025/2091 and 2025/2154 from 16.07.2026.
- European Commission: Table of correspondence for Regulation (EU) 2025/2091Version 1 dated 27.10.2025; pages 3 and 8–9: Documentation/data integrity, Appendix IV and previous Annex 11 sections. Guidance document, not a substitute for the regulatory text.
Sources checked: .
Link veterinary GMP requirements with existing IT documentation evidence
We support you in aligning application areas and current sources, reviewing existing evidence of compatibility, and specifically addressing identified gaps.
- Computer system validation →
Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

